SARS-CoV-2 immune response monitoring:

Does your Anti-SARS-CoV-2 assay detect antibodies formed after vaccination? 

And will your Anti-SARS-CoV-2 assay allow quantitative detection of antibody concentration to evaluate vaccination success?
 

  • [Feb 18, 2021]

To support the IvD & Pharma Industry in their efforts against the COVID-19 pandemic, unique SARS-CoV-2 immunity seroconversion panels are now being developed by Biomex GmbH, Germany.

These post vaccination panels consist of a collection of donors immunized with either BioNTech/Pfizer or Moderna vaccine.

Biomex is currently collecting the following sample set:
 ◊  The existing panel consists of 16 donations from 50 donors containing
     1 mL of serum from each member.
 ◊  The collection period expands over 8 weeks with 2 donations per week.
     Accordingly, this seroconversion panel will have a total size of
     800 serum samples.
 ◊  The first collections have started at the first vaccination.

You can receive the vaccination panel at the end of the collection or as partial shipments.

Please contact us to determine the appropriate panel size for your customized requirements.

For any further questions, feel free to contact us directly at salesno-spam@biomex.de or use our contact form.

← back to news overview